Fruzaqla listed on the PBS

Bowel Cancer Australia welcomes the listing of fruquintinib (Fruzaqla) on the Pharmaceutical Benefits Scheme (PBS) from 1 May 2026.

This treatment option is for adult patients with metastatic bowel cancer when other treatments have not worked or when other treatments are not suitable (i.e. fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and an anti-EGFR agent if appropriate).

Fruzaqla stops tumours from making new blood vessels and therefore slows down the growth of
cancer. Blood vessels would usually provide the tumour with nutrients and oxygen.

Discuss with your oncologist if you are eligible for this treatment.